Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.…
Nuvation Bio (NUVB) On Safusidenib Data And Why The Undervaluation Narrative Persists
Nuvation Bio (NYSE: NUVB) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 310 employees.
The shares were at 3.800 USD on 20 November 2026, down 18.6% over 52 weeks. Its 52-week range is 3.710 USD to 9.750 USD: the price is 61.0% below the high and 2.4% above the low.
Its market capitalisation is 1.34B USD.
Nuvation Bio reports return on equity of -66.9%, an operating margin of -61.2% and revenue up 242.6% year over year.
It holds more cash than debt, a net cash position of 195.24M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 12.45 USD is 227.8% above the current price. The next earnings report is expected on 2 March 2027.